Nanobiotix Stock: Shares Up 4.99% at Close, Boosted by J.P. Morgan Healthcare Conference
Nanobiotix closed up 4.99% at 18.10 euros on January 13, 2026, amid participation by its management in the J.P. Morgan Healthcare Conference from January 12 to 15 in San Francisco. The increase follows a bearish session and is part of a technical momentum indicating a gradual exit from a weak zone.
Performance Amid Moderate Trading Volumes
Nanobiotix's stock closed the session on Tuesday, January 13, 2026, at 18.10 euros, marking a rise of 4.99% from the previous day's close of 17.24 euros. This increase occurred in a context of moderate trading volumes, with only 0.37% of the capital traded during the day. Despite being under pressure over the week with a slight decline of 0.11%, the French biotech specializing in nanomedicine still shows a spectacular annual performance of 509.4%, massively outperforming the Paris market. The management's participation in the J.P. Morgan Healthcare Conference in San Francisco, a major strategic event in the health sector that brings together institutional investors and biotech companies, could be seen as anticipation of potential announcements or discussions on clinical advancements and group financing. The stock has thus crossed the support threshold of 17.24 euros identified the previous day and is approaching the technical resistance located at 19.90 euros, suggesting a possible short-term bullish consolidation phase.
Technical and Fundamental Perspectives
From a technical standpoint, the RSI stands at 39, gradually moving away from the oversold threshold set at 30, indicating a renewed interest from buyers after several sessions of decline. However, the stock remains slightly below its 50-day moving average at 18.31 euros, still showing some short-term fragility. The MACD is in a bearish setup with a MACD line at -0.25 and a negative histogram, indicating a dynamic that still needs confirmation to sustainably reverse. Volatility remains contained at 12.80% over a month, a relatively low level for a biotechnological value in an advanced clinical development phase. On the fundamental side, Nanobiotix enjoys a favorable consensus from analysts with a performance outperform recommendation maintained by Oddo BHF, which raised its price target to 28 euros in mid-December, representing a potential increase of 54.7% from the closing price. Leerink Partners also maintains a constructive outlook with a target of 26 euros. Additionally, in November 2025, the company secured a non-dilutive financing of 71 million dollars from HealthCare Royalty, extending its financial visibility until early 2028, providing significant leeway to continue developing its flagship product NBTXR3 in various oncological indications in partnership with Johnson & Johnson.
